What are Ionis Pharmaceuticals's total assets?

Ionis Pharmaceuticals (IONS) holds $3.4B in total assets, up 22.7% year over year.

How much debt does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals carries $691.7M in total debt against $491.4M of shareholders' equity, a debt-to-equity ratio of 1.41.

How much cash does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals holds $173.4M in cash and equivalents.

Can Ionis Pharmaceuticals cover its short-term obligations?

Its current ratio is 4.10 — current assets exceed current liabilities.

Where does Ionis Pharmaceuticals's balance sheet data come from?

Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Ionis Pharmaceuticals IONS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$173.38M-34.4%	$372.26M+53.8%	$338.34M+1.1%	$297.3M+1.1%	$264.19M-24.3%
Short-term investments	$1.12B-9.4%	$1.58B+12.5%	$1.28B-14.2%	$1.33B-0.8%	$1.23B-5.4%
Inventories	$5.56M-51.7%	$10.05M-19.7%	$10.47M-63.2%	$8.48M-70.5%	$11.5M-62.0%
Prepaid expenses and other current assets	$306.08M+37.5%	$237.09M+8.8%	$243.74M+32.3%	$226.11M+16.1%	$222.57M+27.9%
Contract assets	$73.68M+85.6%	$66.06M-28.3%	$24.61M+37.3%	$52.58M+92.9%	$39.71M+673%
Total current assets	$2.94B+21.4%	$2.99B+14.1%	$2.52B-7.2%	$2.58B+10.6%	$2.42B+0.1%
Property and equipment, net	$142.4M+38.4%	$123.05M+30.6%	$106.12M+28.6%	$111.95M+47.5%	$102.93M+41.4%
Accumulated depreciation	——	——	——	——	——
Operating lease right-of-use assets	$235.06M+47.6%	$238.55M+47.4%	$241.99M+47.2%	$163.93M-1.8%	$159.27M-6.0%
Other non-current assets	$135.56M+2.8%	$171.6M+34.8%	$165.99M+38.0%	$132.1M+11.1%	$131.82M+24.3%
Long-term investments	——	——	——	——	——
Available-for-sale securities	$630.67M-7.4%	$773.71M+18.6%	$700.94M+1.6%	$718.35M+55.9%	$681.35M+19.9%
Equity securities	$77.77M+76.3%	$55.22M+19.3%	$55.47M+13.8%	$25.81M-46.1%	$44.11M-14.3%
Total assets	$3.45B+22.6%	$3.52B+17.3%	$3.03B-1.6%	$2.99B+10.9%	$2.81B+1.8%
Accounts payable	$26.03M+49.1%	$28.08M-34.6%	$14.33M+58.3%	$22.8M+147%	$17.46M+33.4%
Accrued expenses	$36.05M+35.7%	$116.24M+67.0%	$57.02M+40.6%	$46.56M+33.0%	$26.58M+23.4%
Deferred revenue	$69.2M-14.7%	$73.76M-6.6%	$76.99M+1.3%	$75.91M-19.3%	$81.1M-37.8%
Short-term borrowings	$432.5M—	——	——	——	——
Contract liabilities	$75.75M-46.2%	$92M-41.2%	$107.91M-37.9%	$125.1M-33.7%	$140.68M-34.6%
Income taxes payable	$2.87M+2,181%	$2.71M+7,879%	$101K+146%	$81K-71.5%	$126K-94.3%
Accrued interest	——	——	——	——	——
Total current liabilities	$716.59M+186%	$781.57M+153%	$903.46M+197%	$897.24M+193%	$250.29M-23.6%
Deferred tax liabilities	——	——	——	——	——
Operating lease liabilities, non-current	$259.22M+62.6%	$262.38M+62.2%	$262.67M+56.0%	$164.38M-1.2%	$159.39M-5.5%
Other non-current liabilities	$28.27M-49.2%	$28.12M-45.8%	$28.79M-31.0%	$59.07M+41.4%	$55.67M+33.2%
Total liabilities	$2.96B+26.6%	$3.03B+25.6%	$2.42B-0.1%	$2.35B-3.0%	$2.34B-5.3%
Common stock	300M0.0%	300M0.0%	300M0.0%	300M0.0%	300M0.0%
Additional paid-in capital	$3.25B+11.9%	$3.15B+9.6%	$3.05B+7.5%	$2.93B+27.3%	$2.9B+27.8%
Retained earnings	-$2.72B-13.6%	-$2.63B-17.0%	-$2.4B-11.9%	-$2.27B-13.4%	-$2.4B-23.6%
Accumulated other comprehensive income (loss)	-$31.02M-7.2%	-$25.28M+17.9%	-$25.98M-7.5%	-$27.99M+19.7%	-$28.95M+17.2%
Total stockholders' equity	$491.41M+3.3%	$489.09M-16.9%	$617.97M-6.7%	$631.72M+140%	$475.73M+60.4%
Total liabilities and stockholders' equity	$3.45B+22.6%	$3.52B+17.3%	$3.03B-1.6%	$2.99B+10.9%	$2.81B+1.8%
Available-for-Sale Debt Securities - Amortized Cost	$1.75B-8.6%	$2.35B+14.2%	$1.98B-9.1%	$2.05B+13.3%	$1.91B+2.0%
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	$11.32M—	$29.29M—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	$11.32M—	$29.29M—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$1.02B—	$278.87M—	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	$1.02B—	$278.87M—	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position	$2.73M—	$246K—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	$11.32M—	$29.29M—	——	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	$1.03B—	$308.17M—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$1.02B—	$278.87M—	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$1.03B—	$308.17M—	——	——	——
Available For Sale Securities Debt Securities Current	$1.12B-9.4%	$1.58B+12.5%	$1.28B-14.2%	$1.33B-0.8%	$1.23B-5.4%
Other current assets	$306.08M+37.5%	$237.09M+8.8%	$243.74M+32.3%	$226.11M+16.1%	$222.57M+27.9%
Current Equity Amortized Cost	$21.9M-37.5%	$16.8M-52.0%	$16.8M-52.0%	$16.8M-52.0%	$35.01M0.0%
Equity Securities (FV-NI) - Cost Basis	$21.9M-37.5%	$16.8M-52.0%	$16.8M-52.0%	$16.8M-52.0%	$35.01M0.0%
Deferred Tax Assets and Other Non-Current Assets	$135.56M+2.8%	$12.76M-9.0%	$165.99M+38.0%	$132.1M+11.1%	$131.82M+24.3%
Deferred Tax Assets - Tax Credit Carryforwards	——	——	——	——	——
Equity Amortized Cost	$21.9M-37.5%	$16.8M-52.0%	$16.8M-52.0%	$16.8M-52.0%	$35.01M0.0%
Investments - Amortized Cost Basis	$1.75B-8.6%	$2.35B+14.2%	$1.98B-9.1%	$2.05B+13.3%	$1.91B+2.0%
Investments - Cost Basis	$21.9M-37.5%	$16.8M-52.0%	$16.8M-52.0%	$16.8M-52.0%	$35.01M0.0%
Net Investment in Lease	$235.06M+47.6%	$238.55M+47.4%	$241.99M+47.2%	$163.93M-1.8%	$159.27M-6.0%
Net Operating Loss Carryforwards	——	——	——	——	——
Long-term marketable securities	$630.67M-7.4%	$773.71M+18.6%	$700.94M+1.6%	$718.35M+55.9%	$681.35M+19.9%
Operating lease right-of-use assets	$235.06M+47.6%	$238.55M+47.4%	$241.99M+47.2%	$163.93M-1.8%	$159.27M-6.0%
Other non-current assets	$135.56M+2.8%	$171.6M+34.8%	$165.99M+38.0%	$132.1M+11.1%	$131.82M+24.3%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$1.75B-7.2%	$2.31B+12.1%	$1.9B-11.5%	$1.99B+11.7%	$1.88B+1.3%
Operating Lease Right-of-Use Assets in Other Assets	$235.06M+47.6%	$238.55M+47.4%	$241.99M+47.2%	$163.93M-1.8%	$159.27M-6.0%
Software and Technology Licenses, Net	$135.56M+2.8%	$171.6M+34.8%	$165.99M+38.0%	$132.1M+11.1%	$131.82M+24.3%
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
Accrued Manufacturing Costs	$36.05M+35.7%	$116.24M+67.0%	$57.02M+40.6%	$46.56M+33.0%	$26.58M+23.4%
Accrued Progress Collections and Price Adjustments	$75.75M-46.2%	$92M-41.2%	$107.91M-37.9%	$125.1M-33.7%	$140.68M-34.6%
Other Commercial Liabilities	$126.55M+23.2%	$106.09M-2.2%	$99.31M-20.2%	$98.96M-13.4%	$102.74M-3.1%
Accrued Income Taxes, Current	$2.87M+2,181%	$2.71M+7,879%	$101K+146%	$81K-71.5%	$126K-94.3%
Accrued Liabilities, Current	$126.55M+23.2%	$106.09M-2.2%	$99.31M-20.2%	$98.96M-13.4%	$102.74M-3.1%
Debt, current	$432.5M—	——	——	——	——
Compensation and benefits	$36.05M+35.7%	$116.24M+67.0%	$57.02M+40.6%	$46.56M+33.0%	$26.58M+23.4%
Other accrued liabilities	$23.39M+4.9%	$22.74M+145%	$24.8M+147%	$22.81M+159%	$22.3M+123%
Contract Liabilities, Non-Current	$75.75M-46.2%	$92M-41.2%	$107.91M-37.9%	$125.1M-33.7%	$140.68M-34.6%
Debt Maturity - 2027	——	——	——	——	——
Debt Maturity - Thereafter	——	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	——	——	——	——	——
Deferred Tax Liabilities - Leasing Arrangements	——	——	——	——	——
Deferred revenue, net of current portion	$75.75M-46.2%	$92M-41.2%	$107.91M-37.9%	$125.1M-33.7%	$140.68M-34.6%
Total debt	$691.72M+334%	$2.46B+1,005%	$893.58M+320%	$794.5M+277%	$159.39M-25.2%
Unrecognized Tax Benefits	——	——	——	——	——
Unrecognized Tax Benefits - Impacting Effective Tax Rate	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$25K—	$17K—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss	368—	110—	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	165.9M+4.3%	163.3M+3.4%	161.1M+2.1%	159.2M+9.0%	159M+9.0%
Additional paid-in capital	$3.25B+11.9%	$3.15B+9.6%	$3.05B+7.5%	$2.93B+27.3%	$2.9B+27.8%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$166K+4.4%	$163K+3.2%	$161K+1.9%	$159K+8.9%	$159K+8.9%
Investments - Gross Unrealized Losses	$1.03B—	$308.17M—	——	——	——
Unrealized Gains on Investments	$1.11M-55.8%	$4.22M+62.9%	$3.61M-40.6%	$2.51M+633%	$2.5M+194%
Unrealized Losses on Investments (Before Tax)	$2.73M+58.3%	$246K-92.9%	$376K-50.7%	$1.37M-74.5%	$1.73M-71.3%
Cumulative Cost Basis	$1.75B-8.6%	$2.35B+14.2%	$1.98B-9.1%	$2.05B+13.3%	$1.91B+2.0%
Accrued Clinical Expenses	$53.33M—	$53.66M—	$54.84M—	——	——
Accrued Commercial Expenses Current	$40.47M+458%	$15.56M+333%	$15.02M+199%	$12.36M+170%	$7.26M+53.1%
Accrued In Licensing Fees Current	$6.66M-9.8%	$8.59M+8.0%	$7.77M+9.7%	$7.24M-31.7%	$7.37M+14.6%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$2.73M+58.3%	$246K-92.9%	$376K-50.7%	$1.37M-74.5%	$1.73M-71.3%
Gross Unrealized Gains	$1.11M-55.8%	$4.22M+62.9%	$3.61M-40.6%	$2.51M+633%	$2.5M+194%
Total	$1.75B-8.6%	$2.35B+14.2%	$1.98B-9.1%	$2.05B+13.3%	$1.91B+2.0%
Available For Sale Securities Debt Maturities After Two Through Three And One Half Years Percentage	6%—	5%—	——	——	——
Available For Sale Securities Debt Maturities After One Through Two Years Percentage	27%—	25%—	——	——	——
Available For Sale Securities Debt Maturities Total Percentage	100%—	100%—	——	——	——
Available For Sale Securities Debt Maturities Within Two Years Percentage	94%—	95%—	——	——	——
Available For Sale Securities Debt Maturities Within One Year Percentage	67%—	70%—	——	——	——
Available for sale investments	$1.75B-8.7%	$2.35B+14.4%	$1.98B-9.2%	$2.05B+13.7%	$1.91B+2.3%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%
Common stock, shares issued (in shares)	$165.9M+4.3%	$163.3M+3.4%	$161.14M+2.1%	$159.2M+9.0%	$159.04M+9.0%
Common Stock, Shares, Outstanding	$165.9M+4.3%	$163.3M+3.4%	$161.14M+2.1%	$159.2M+9.0%	$159.04M+9.0%
Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent	$2.14M+81.7%	$201K-93.4%	$230K-44.3%	$490K-79.0%	$1.18M-45.7%
Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current	$766K-9.9%	$1.94M+20.5%	$1.28M-55.8%	$478K+613%	$850K+378%
Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent	$339K-79.4%	$2.29M+132%	$2.33M-26.8%	$2.03M+638%	$1.65M+145%
Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current	$594K+8.2%	$45K-88.7%	$146K-58.2%	$876K-71.1%	$549K-85.7%
Debt Securities, Available-for-sale, Amortized Cost, Noncurrent	$632.47M-7.1%	$771.63M+17.9%	$698.84M+1.7%	$716.81M+54.9%	$680.88M+19.5%
Amortized cost of available-for-sale debt securities, current	$1.12B-9.4%	$1.58B+12.5%	$1.28B-14.1%	$1.33B-1.0%	$1.23B-5.6%
Debt Securities Available For Sale And Equity Securities Fv Ni	$1.83B-6.8%	$2.41B+14.5%	$2.04B-8.7%	$2.07B+12.1%	$1.96B+1.9%
Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Gain	$66.78M+142%	$58.65M+112%	$58.04M+84.3%	$27.55M+7.3%	$27.54M+5.2%
Debt Securities Available For Sale And Equity Securities Fv Ni Cost	$1.77B-9.1%	$2.37B+13.1%	$2B-9.8%	$2.06B+12.1%	$1.95B+2.0%
Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss	$12.54M-29.1%	$16.26M-5.4%	$16.15M+29.4%	$17.4M-2.4%	$17.68M+18.7%
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	$25K—	$17K—	——	——	——
Less than 12 months	$1.02B—	$278.87M—	——	——	——
12 months or more	$11.32M—	$29.29M—	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$2.71M—	$229K—	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss	$2.73M—	$246K—	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	$1.03B—	$308.17M—	——	——	——
Deferred Tax Assets Capitalized Research And Development Expenses	——	——	——	——	——
Deferred Tax Assets Financing Arrangements	——	——	——	——	——
Deferred Tax Assets, Goodwill and Intangible Assets	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets Leasing Arrangements	——	——	——	——	——
Deferred Tax Assets, Net	——	——	——	——	——
Deferred Tax Assets Liabilities Net Before Valuation Allowance	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	——	——	——	——
Deferred Tax Assets Sale Of Future Royalties	——	——	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	——	——	——	——
Deferred Tax Assets, Valuation Allowance	——	——	——	——	——
Deferred Tax Liabilities, Other	——	——	——	——	——
Deferred Tax Liabilities, Property, Plant and Equipment	——	——	——	——	——
Equity Securities Fv Ni Accumulated Gross Unrealized Gain	$65.67M+162%	$54.43M+117%	$54.44M+114%	$25.04M-1.2%	$25.04M-1.1%
Equity Securities Fv Ni Accumulated Gross Unrealized Loss	$9.8M-38.5%	$16.01M+16.4%	$15.77M+34.6%	$16.04M+28.6%	$15.95M+79.6%
Cost	$21.9M-37.5%	$16.8M-52.0%	$16.8M-52.0%	$16.8M-52.0%	$35.01M0.0%
Escrow Deposits	——	——	——	——	——
Inventory Current And Noncurrent	$26.16M—	——	——	——	——
Inventory Currentand Noncurrent	——	——	——	——	——
Inventory Finished Goods Net	$990K—	——	——	——	——
Inventory Raw Materials Net	$490K—	——	——	——	——
Inventory Work In Process Net	$24.68M—	——	——	——	——
Liability Related To Sale Of Future Royalties Net Noncurrent	$557.77M—	$551.35M—	$545.18M—	——	——
Loans Payable To Bank	——	——	——	——	——
2028	——	——	——	——	——
2029	——	——	——	——	——
2029	——	——	——	——	——
2030	——	——	——	——	——
Thereafter	——	——	——	——	——
2027	——	——	——	——	——
Long Term Obligations	——	——	——	——	——
Maximum Amount Of Payments Receivable For Additional Milestones	——	——	——	——	——
Number Of Privately Held Companies In Which Entity Has Equity Investment	4—	5—	——	——	——
Number Of Publicly Held Companies In Which Entity Has Equity Investment	4—	3—	——	——	——
Other accrued liabilities	$26.1M+27.4%	$28.29M+45.3%	$21.68M-1.7%	$19.78M+15.5%	$20.49M+8.2%
Unrecognized tax benefits	——	——	——	——	——
Amount that if recognized, would affect the effective tax rate or regulatory liability	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Ionis Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Ionis Pharmaceuticals's total assets?: Ionis Pharmaceuticals (IONS) holds $3.4B in total assets, up 22.7% year over year.
How much debt does Ionis Pharmaceuticals have?: Ionis Pharmaceuticals carries $691.7M in total debt against $491.4M of shareholders' equity, a debt-to-equity ratio of 1.41.
How much cash does Ionis Pharmaceuticals have?: Ionis Pharmaceuticals holds $173.4M in cash and equivalents.
Can Ionis Pharmaceuticals cover its short-term obligations?: Its current ratio is 4.10 — current assets exceed current liabilities.
Where does Ionis Pharmaceuticals's balance sheet data come from?: Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.